Krystal Biotech, Inc. Common Stock
$336.67
-$2.08 (-0.61%)
$335.50Day Range$341.35
Key Statistics
Market Cap
$9.97B
Shares Outstanding
29.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 20, 2017
Round Lot
40
Locale
US
Trading Data
Day Open
$340.00
Day High
$341.35
Day Low
$335.50
Volume
1.00M
VWAP
$336.92
Prev Close
$338.75
Transactions
--
Acc. Volume
--
About Krystal Biotech, Inc. Common Stock
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836295 employees2100 WHARTON STREET, PITTSBURGH, PA, 15203(412) 586-5830IPO Sep 20, 2017US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001711279
- Composite FIGI
- BBG00HDGRHH7
- Share Class FIGI
- BBG00HDGRHJ5
- Ticker Root
- KRYS
- SIC Code
- 2836
About Krystal Biotech, Inc. Common Stock (KRYS) Stock
Krystal Biotech, Inc. Common Stock (KRYS) closed the 2026-09-18 session at $336.67, down 0.61% versus the previous close (-2.08). The stock opened at $340.00 and traded between $335.50 and $341.35 during that session. Session trading volume was 1.0M shares. The volume-weighted average price (VWAP) is $336.92.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Krystal Biotech, Inc. Common Stock has a market capitalization of $9.97 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. KRYS is listed on the XNAS exchange. The company employs approximately 295 people. Krystal Biotech, Inc. Common Stock is headquartered in PITTSBURGH, PA. The recorded listing date is 2017-09-20.
On this page you can find market KRYS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.